WuXi Biologics (HK:2269), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Friday the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs) in the second drug substance line of its MFG20 facility at its Hangzhou site.

The company said that this accomplishment demonstrates its capabilities in single-use technology (SUT) application for large-scale production.

WuXi Biologics' process technologies demonstrated a reduction of almost 70% in protein production costs per gram, while advanced mass transfer technology delivered a 20% increase in protein yield per batch.

Dr. Chris Chen, CEO of WuXi Biologics, said: "Over the past six years, by leveraging continuous process innovation, the company has applied SUT manufacturing in over 300 batches of scaled production ranging from 4,000L to 16,000L across multiple facilities, achieving a 99% production success rate over the past three years. Single-use technology manufacturing can attain COGs comparable to stainless-steel systems – while being the more eco-friendly approach – and it provides clients with greater flexibility and a wider range of options for patients worldwide. Moving forward, we remain committed to exploring and applying cutting-edge technologies to empower partners in delivering high-quality innovative therapies to patients worldwide."